Evotec SE (EVT.DE)
EUR 6.4
(9.9%)
EUR 6.4
(9.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -47.5 Million EUR | -957.05% |
| 2022 | 12.49 Million EUR | -54.26% |
| 2021 | 27.32 Million EUR | -43.7% |
| 2020 | 48.52 Million EUR | -22.48% |
| 2019 | 62.59 Million EUR | -19.19% |
| 2018 | 77.46 Million EUR | 106.6% |
| 2017 | 37.49 Million EUR | 19.63% |
| 2016 | 31.34 Million EUR | 169.26% |
| 2015 | 11.64 Million EUR | 282.42% |
| 2014 | -6.38 Million EUR | 70.11% |
| 2013 | -21.35 Million EUR | -566.8% |
| 2012 | -3.2 Million EUR | -161.49% |
| 2011 | 5.2 Million EUR | 203.62% |
| 2010 | 1.71 Million EUR | 104.05% |
| 2009 | -42.29 Million EUR | 42.22% |
| 2008 | -73.21 Million EUR | -25.97% |
| 2007 | -58.11 Million EUR | -58.08% |
| 2006 | -36.76 Million EUR | -11.52% |
| 2005 | -32.96 Million EUR | -8.93% |
| 2004 | -30.26 Million EUR | 8.71% |
| 2003 | -33.15 Million EUR | -38.64% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -43.23 Million EUR | -281.5% |
| 2024 Q1 | -27.42 Million EUR | -11.35% |
| 2023 Q2 | -36.28 Million EUR | -389.96% |
| 2023 Q4 | -24.62 Million EUR | -102.05% |
| 2023 Q1 | 12.51 Million EUR | -66.79% |
| 2023 Q3 | -12.18 Million EUR | 66.42% |
| 2023 FY | -107.08 Million EUR | -957.05% |
| 2022 FY | 12.49 Million EUR | -54.26% |
| 2022 Q1 | 125.36 Million EUR | 738.93% |
| 2022 Q2 | -3.77 Million EUR | -103.01% |
| 2022 Q3 | -13.52 Million EUR | -258.86% |
| 2022 Q4 | 37.68 Million EUR | 378.56% |
| 2021 FY | 27.32 Million EUR | -43.7% |
| 2021 Q3 | 17.73 Million EUR | 1054.07% |
| 2021 Q4 | 14.94 Million EUR | -15.76% |
| 2021 Q2 | 1.53 Million EUR | -77.32% |
| 2021 Q1 | 6.77 Million EUR | -48.8% |
| 2020 Q2 | 2.82 Million EUR | -82.47% |
| 2020 FY | 48.52 Million EUR | -22.48% |
| 2020 Q4 | 13.23 Million EUR | -19.13% |
| 2020 Q1 | 16.09 Million EUR | -0.46% |
| 2020 Q3 | 16.36 Million EUR | 480.05% |
| 2019 Q2 | 4.97 Million EUR | -73.88% |
| 2019 FY | 62.59 Million EUR | -19.19% |
| 2019 Q1 | 19.05 Million EUR | 6.2% |
| 2019 Q3 | 22.38 Million EUR | 349.76% |
| 2019 Q4 | 16.16 Million EUR | -27.78% |
| 2018 Q1 | 6.53 Million EUR | -43.88% |
| 2018 Q3 | 37.82 Million EUR | 149.54% |
| 2018 Q2 | 15.15 Million EUR | 132.11% |
| 2018 FY | 77.46 Million EUR | 106.6% |
| 2018 Q4 | 17.94 Million EUR | -52.56% |
| 2017 Q4 | 11.63 Million EUR | 52.67% |
| 2017 Q1 | 9.71 Million EUR | -11.45% |
| 2017 Q2 | 8.52 Million EUR | -12.21% |
| 2017 Q3 | 7.62 Million EUR | -10.57% |
| 2017 FY | 37.49 Million EUR | 19.63% |
| 2016 Q3 | 11.98 Million EUR | 112.35% |
| 2016 Q2 | 5.64 Million EUR | 105.72% |
| 2016 Q1 | 2.74 Million EUR | 525.43% |
| 2016 Q4 | 10.96 Million EUR | -8.52% |
| 2016 FY | 31.34 Million EUR | 169.26% |
| 2015 Q4 | -645 Thousand EUR | -1.26% |
| 2015 Q3 | -637 Thousand EUR | -103.93% |
| 2015 Q2 | 16.22 Million EUR | 591.58% |
| 2015 Q1 | -3.3 Million EUR | -240.78% |
| 2015 FY | 11.64 Million EUR | 282.42% |
| 2014 FY | -6.38 Million EUR | 70.11% |
| 2014 Q2 | -83 Thousand EUR | 97.62% |
| 2014 Q4 | 2.34 Million EUR | 145.43% |
| 2014 Q3 | -5.16 Million EUR | -6116.87% |
| 2014 Q1 | -3.48 Million EUR | 79.65% |
| 2013 Q1 | -2.71 Million EUR | 55.27% |
| 2013 FY | -21.35 Million EUR | -566.8% |
| 2013 Q4 | -17.11 Million EUR | -10661.73% |
| 2013 Q3 | 162 Thousand EUR | 109.6% |
| 2013 Q2 | -1.68 Million EUR | 37.89% |
| 2012 Q4 | -6.07 Million EUR | -495.06% |
| 2012 Q2 | 2.62 Million EUR | 303.41% |
| 2012 Q3 | 1.53 Million EUR | -41.38% |
| 2012 FY | -3.2 Million EUR | -161.49% |
| 2012 Q1 | -1.28 Million EUR | 70.16% |
| 2011 Q2 | 1.73 Million EUR | 313.7% |
| 2011 Q1 | -810 Thousand EUR | -215.55% |
| 2011 FY | 5.2 Million EUR | 203.62% |
| 2011 Q4 | -4.31 Million EUR | -150.19% |
| 2011 Q3 | 8.6 Million EUR | 397.11% |
| 2010 Q4 | 701 Thousand EUR | 4.32% |
| 2010 Q1 | -1.47 Million EUR | 84.26% |
| 2010 Q2 | 1.81 Million EUR | 223.2% |
| 2010 Q3 | 672 Thousand EUR | -63.0% |
| 2010 FY | 1.71 Million EUR | 104.05% |
| 2009 FY | -42.29 Million EUR | 42.22% |
| 2009 Q1 | -20.24 Million EUR | 46.74% |
| 2009 Q2 | -8.86 Million EUR | 56.21% |
| 2009 Q3 | -3.81 Million EUR | 56.98% |
| 2009 Q4 | -9.36 Million EUR | -145.53% |
| 2008 Q3 | -8.3 Million EUR | 26.17% |
| 2008 Q4 | -38.02 Million EUR | -357.8% |
| 2008 Q2 | -11.24 Million EUR | 21.77% |
| 2008 Q1 | -14.37 Million EUR | -459.1% |
| 2008 FY | -73.21 Million EUR | -25.97% |
| 2007 Q1 | - EUR | 100.0% |
| 2007 FY | -58.11 Million EUR | -58.08% |
| 2007 Q2 | -6.67 Million EUR | 0.0% |
| 2007 Q4 | 4 Million EUR | 134.47% |
| 2007 Q3 | -11.61 Million EUR | -73.92% |
| 2006 FY | -36.76 Million EUR | -11.52% |
| 2006 Q3 | -5.85 Million EUR | -28.36% |
| 2006 Q4 | -11.63 Million EUR | -98.55% |
| 2006 Q1 | -5.88 Million EUR | -13.95% |
| 2006 Q2 | -4.56 Million EUR | 22.48% |
| 2005 Q3 | - EUR | 100.0% |
| 2005 Q4 | -5.16 Million EUR | 0.0% |
| 2005 Q1 | -7.7 Million EUR | -31.67% |
| 2005 Q2 | -8.24 Million EUR | -6.96% |
| 2005 FY | -32.96 Million EUR | -8.93% |
| 2004 FY | -30.26 Million EUR | 8.71% |
| 2004 Q3 | - EUR | 100.0% |
| 2004 Q1 | -7.04 Million EUR | -2.92% |
| 2004 Q2 | -8.06 Million EUR | -14.48% |
| 2004 Q4 | -5.85 Million EUR | 0.0% |
| 2003 Q4 | -6.84 Million EUR | -14.96% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | -33.15 Million EUR | -38.64% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | -5.95 Million EUR | 0.0% |
| 2002 FY | -23.91 Million EUR | -87.72% |
| 2001 FY | -12.73 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| MPH Health Care AG | 15.7 Million EUR | 402.592% |
| Apontis Pharma AG | -15.1 Million EUR | -214.616% |
| Dermapharm Holding SE | 182.89 Million EUR | 125.975% |
| MERCK Kommanditgesellschaft auf Aktien | 3.6 Billion EUR | 101.316% |
| PharmaSGP Holding SE | 40.91 Million EUR | 216.114% |
| SynBiotic SE | -7.58 Million EUR | -526.58% |